AU2019366996A1 - Polymer-lipids and compositions - Google Patents

Polymer-lipids and compositions Download PDF

Info

Publication number
AU2019366996A1
AU2019366996A1 AU2019366996A AU2019366996A AU2019366996A1 AU 2019366996 A1 AU2019366996 A1 AU 2019366996A1 AU 2019366996 A AU2019366996 A AU 2019366996A AU 2019366996 A AU2019366996 A AU 2019366996A AU 2019366996 A1 AU2019366996 A1 AU 2019366996A1
Authority
AU
Australia
Prior art keywords
composition
optionally substituted
polymer
carbon atoms
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019366996A
Other languages
English (en)
Other versions
AU2019366996A8 (en
Inventor
Daniel Griffith Anderson
James C. Kaczmarek
Kevin John Kauffman
Asha Kumari Patel
Luke Hyunsik Rhym
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of AU2019366996A1 publication Critical patent/AU2019366996A1/en
Publication of AU2019366996A8 publication Critical patent/AU2019366996A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/52—Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
    • C08G63/56—Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds other than from esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AU2019366996A 2018-10-26 2019-10-25 Polymer-lipids and compositions Abandoned AU2019366996A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751116P 2018-10-26 2018-10-26
US62/751,116 2018-10-26
PCT/US2019/058064 WO2020086965A1 (en) 2018-10-26 2019-10-25 Polymer-lipids and compositions

Publications (2)

Publication Number Publication Date
AU2019366996A1 true AU2019366996A1 (en) 2021-05-27
AU2019366996A8 AU2019366996A8 (en) 2021-06-10

Family

ID=68582418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019366996A Abandoned AU2019366996A1 (en) 2018-10-26 2019-10-25 Polymer-lipids and compositions

Country Status (5)

Country Link
US (1) US11608412B2 (de)
EP (1) EP3870629A1 (de)
AU (1) AU2019366996A1 (de)
CA (1) CA3117781A1 (de)
WO (1) WO2020086965A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700965A1 (de) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly(beta-aminoester) und deren verwendungen
AU2019374871B2 (en) * 2018-11-09 2025-09-11 Translate Bio, Inc. PEG lipidoid compounds
JP2022532256A (ja) 2019-05-16 2022-07-13 ジェム イノヴ 生分解性マイクロカプセルの調製方法及びこの方法で得たマイクロカプセル
US20230381113A1 (en) * 2020-09-28 2023-11-30 The Johns Hopkins University Polymers and nanoparticle formulations for systemic nucleic acid delivery
FR3116212B1 (fr) 2020-11-18 2022-12-30 Gem Innov Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues
US12433847B2 (en) 2021-03-09 2025-10-07 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759913A (en) 1952-05-20 1956-08-21 Hercules Powder Co Ltd Copolymers of compounds containing activated ethylene double bonds with active hydrogen compounds
DE1668502A1 (de) 1967-11-07 1971-09-02 Nii Monomerow Dlja Sintetitsch Verfahren zur Herstellung von Akryl-und Methakrylestern
US3963771A (en) 1970-09-02 1976-06-15 Union Carbide Corporation Amine acrylate addition reaction products
DE2520814A1 (de) 1975-05-09 1976-11-18 Bayer Ag Lichtstabilisierung von polyurethanen
JPS599898B2 (ja) 1975-09-23 1984-03-06 富士写真フイルム株式会社 シヤシンカンコウザイリヨウ
US4224365A (en) 1978-05-15 1980-09-23 Glass Containers Corporation Method of coating glass containers and product
US4348511A (en) 1980-05-07 1982-09-07 Ciba-Geigy Corporation Process for the preparation of crosslinked, unsaturated polymers and the polymers thus obtained
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5180424A (en) 1991-10-07 1993-01-19 Westvaco Corporation Michael addition aminopolyester resins as dilution extenders for zinc-containing metal resinate inks
US5364634A (en) 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
AU673160B2 (en) 1992-02-28 1996-10-31 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5525357A (en) 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
KR100283601B1 (ko) 1993-02-19 2001-03-02 아만 히데아키 글리세롤 유도체, 디바이스 및 의약 조성물
JPH0892369A (ja) 1994-07-29 1996-04-09 Toyo Ink Mfg Co Ltd 硬化性液状樹脂組成物およびその硬化物の製造方法
US5770637A (en) 1996-05-01 1998-06-23 Johnson & Johnson Vision Products, Inc. Anti-bacterial, UV absorbable, tinted, metal-chelating polymers
DE19626567A1 (de) 1996-07-03 1998-01-08 Basf Ag Polyurethane
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US5904927A (en) 1997-03-14 1999-05-18 Northeastern University Drug delivery using pH-sensitive semi-interpenetrating network hydrogels
US5962520A (en) 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
DE19822602A1 (de) 1998-05-20 1999-11-25 Goldschmidt Ag Th Verfahren zur Herstellung von Polyaminosäureestern durch Veresterung von sauren Polyaminosäuren oder Umesterung von Polyaminosäureestern
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
US20010048940A1 (en) 1999-06-18 2001-12-06 Jennifer D. Tousignant Cationic amphiphile micellar complexes
US6444725B1 (en) 2000-01-21 2002-09-03 3M Innovative Properties Company Color-changing dental compositions
DE60120416T2 (de) 2000-08-11 2006-12-14 Dentsply International Inc. Polyaminoester und ihre verwendung in dentalmassen
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP2447370B1 (de) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MikroRNA-Moleküle
AU2003272187A1 (en) 2002-02-01 2004-01-06 Montana State University Novel nanoparticles and use thereof
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
EP1393718A1 (de) 2002-08-29 2004-03-03 OctoPlus Sciences B.V. Kolloidal Wirkstoffträgersystem
WO2004060968A1 (fr) 2002-12-04 2004-07-22 Flamel Technologies Polyaminoacides fonctionnalises par au moins un groupement (oligo)aminoacide et leurs applications notamment therapeutiques
US7309757B2 (en) 2003-06-20 2007-12-18 Agency For Science, Technology And Research Polymers for the delivery of bioactive agents and methods of their preparation
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
JP2007510160A (ja) 2003-10-28 2007-04-19 アリックス インコーポレイテッド ホログラフィック光トラッピングを用いて物質を操作し、処理するためのシステム及び方法
EP1737879B1 (de) 2004-04-19 2012-10-10 Archemix LLC Aptamer-vermittelte intrazelluläre verabreichung von therapeutischen oligonukleotiden
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
EP2046266A4 (de) 2006-07-21 2009-11-04 Massachusetts Inst Technology Endmodizifierte poly(beta-amino-ester) und ihre verwendung
US20100196492A1 (en) 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
US8163861B2 (en) 2009-01-15 2012-04-24 Living Proof, Inc. Beta-amino ester compounds and uses thereof
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
EP2525778B1 (de) * 2010-01-19 2018-08-01 Polypid Ltd. Nucleinsäurematrixzusammensetzungen mit verzögerter freisetzung
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20140271861A1 (en) * 2011-07-27 2014-09-18 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
DE102014215437A1 (de) 2014-08-05 2015-11-05 Basf Se Kolonne zur thermischen Behandlung eines Fluids
GB201413907D0 (en) 2014-08-06 2014-09-17 Nat Univ Ireland Hyberbranched poly(beta-amino ester) for gene therapy

Also Published As

Publication number Publication date
CA3117781A1 (en) 2020-04-30
WO2020086965A1 (en) 2020-04-30
WO2020086965A8 (en) 2020-06-18
US11608412B2 (en) 2023-03-21
WO2020086965A9 (en) 2020-07-16
EP3870629A1 (de) 2021-09-01
US20200172663A1 (en) 2020-06-04
AU2019366996A8 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US11608412B2 (en) Polymer-lipids and compositions
US11679165B2 (en) Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US11041069B2 (en) Gene delivery carrier
US9895443B2 (en) Multi-tailed lipids and uses thereof
CA2831392C (en) Conjugated lipomers and uses thereof
WO2019090097A1 (en) Amino-polyesters for drug delivery
US20170073311A1 (en) Suprametallogels and uses thereof
WO2014179562A1 (en) 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US20240316216A1 (en) Lipid nanoparticles for drug delivery to microglia in the brain
WO2016004202A1 (en) Polyamine-fatty acid derived lipidoids and uses thereof
US12583817B2 (en) Ionizable lipids and compositions and uses thereof
CA3111278A1 (en) Ionizable lipidoids and their uses
US20250049714A1 (en) Synthesis of ester, carbonate, and carbamate-derived novel biodegradable ionizable lipids from methyl ricinoleate or methyl 12-hydroxystearate and its applications
US20240226302A1 (en) Biodegradable lipids and formulations for intramuscular, in vitro, and ex vivo transfection of mrna
WO2023102024A1 (en) POLY(β-AMINO ESTER) MICROPARTICLES FOR MICRONUTRIENT FORTIFICATION
US20250205158A1 (en) Biodegradable lipids and formulations for delivery of mrna
US20240343760A1 (en) Peptides for cell-type specific targeting of the retina
HK40100638A (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2025188636A1 (en) Ionizable lipids for messenger rna delivery
HK1251901B (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2016025643A1 (en) Brush-poly(glycoamidoamine)-lipids and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 21 , PAGE(S) 4539 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME MASSACHUSETTS INSTITUTE OF TECHNOLOGY, APPLICATION NO. 2019366996, UNDER INID (72) CORRECT THE CO-INVENTOR TO KACZMAREK, JAMES C.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period